ADELAIDE, Australia, December 15, 2022 (GLOBE NEWSWIRE) — Bionomics Limited BNOXBNO)), (Bionomics or the Company), a clinical-stage biopharmaceutical company developing novel allosteric ion channel modulators with the promise of transforming the lives of patients suffering from severe central nervous system disorders (CNS) Diseases with High Unmet Medical Needs, today announced the appointment of Spyridon “Spyros” Papapetropoulos, MD, as President and Chief Executive Officer (chairman), effective January 5, 2023. Errol B. De Souza, Ph.D., who has served as Executive Chairman of Bionomics since November 2018, will continue in that role through December 31, 2022 to ensure a seamless transition, and will resume the role of Non-Executive Chairman of the Board of Directors effective January 1, 2023.

Spyros is an experienced biopharmaceutical executive, distinguished neuroscientist/neurologist and change agent with a 25-year career focused on CNS disorders. He has held various positions of increasing responsibility in CNS-focused start-ups/small, medium and large biopharmaceutical companies. Since 2020, he has been Chief Medical Officer of Vigil Neuroscience Inc, a Nasdaq-listed biopharmaceutical company developing a pipeline of targeted neuroimmunotherapeutics to treat neurodegenerative diseases. Prior to joining Vigil, he was Chief Development Officer and SVP, Head of Development at Acadia Pharmaceuticals Inc., CEO at SwanBio Therapeutics and EVP of Research & Development and Chief Medical Officer at Cavion. Prior to Cavion, he held senior/executive positions at Biogen Inc., Allergan plc, Pfizer Inc. and Teva Pharmaceuticals Inc. Spyros has submitted multiple INDs and has overseen a broad spectrum of CNS biopharmaceutical development programs (small molecules, biologics, gene therapy) resulting in successful regulatory submissions (>20 INDs and multiple NDAs/BLAs) and new product launches worldwide. Spyros received his MD and PhD in Greece from the University of Patras,…